A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Blood Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | April 2007 |
| End Date: | April 2012 |
A Phase I Dose Escalation Study of Oral SB939 When Administered Thrice Weekly (Every Other Day) for 3 Weeks in a 4-week Cycle in Patients With Advanced Malignancies
This is an open label, dose escalation study with 3 arms (Arms A, B, and C). Arm A will
assess the safety and tolerability of escalating doses of SB939 in cohorts of patients with
advanced solid tumors. Arm B will assess the safety and tolerability of escalating doses in
cohorts of patients with advanced hematologic malignancies. Arm C will assess the safety and
tolerability of SB939 in combination with standard azacitidine therapy.
We found this trial at
2
sites
M. D. Anderson Cancer Center Welcome to UF Health Cancer Center at Orlando Health. For...
Click here to add this to my saved trials
University of Wisconsin-Madison In achievement and prestige, the University of Wisconsin-Madison has long been recognized...
Click here to add this to my saved trials